4MT1060

4MT1060 is a small molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), developed by 4M Therapeutics. It is being investigated as a potential treatment for neuropsychiatric and neurodegenerative diseases, with particular focus on central nervous system disorders such as those related to SYNGAP1 loss-of-function variants. These variants are associated with intellectual disability, autism spectrum disorder, and seizures. The drug is currently in preclinical development and has not yet entered clinical trials[1][2][3][8]. The mechanism of action involves inhibition of GSK-3β, a key enzyme implicated in neuroplasticity and cognition[1][2].